Delivery Order SPE2DB24D3014-SPE2DB25FKUBV
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,121.79 to AmerisourceBergen Drug Corp for the supply of Trulicity 4.5 mg/0.5 ml pens on July 15, 2025. This firm fixed-price delivery order, designated as a non-competitive award under the company's existing indefinite delivery contract with DLA, is scheduled for completion by July 16, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Trulicity is a diabetes medication...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,000.54 for Trulicity 1.5 mg/0.5 ml pens on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Trulicity is a diabetes medication commonly utilized within military and federal healthcare systems, reflecting...
- The Defense Logistics Agency awarded a delivery order valued at $14,757.50 to AmerisourceBergen Drug Corp for the supply of Trulicity 3 mg/0.5 mL pens on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Trulicity is a diabetes treatment medication commonly used within military and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,956.49 to AmerisourceBergen Drug Corp for the supply of Trulicity 0.75 mg/0.5 mL pens on August 25, 2025, with completion scheduled for August 26, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,868.44 to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 mL pens on August 22, 2025, with an ultimate completion date of August 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, valued at $1,724.06, for the supply of Trulicity 1.5 mg/0.5 mL pens on September 19, 2025, with completion scheduled for September 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Trulicity is a diabetes medication commonly utilized across military and federal...
- The Defense Logistics Agency awarded a $3,348.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Trulicity 4.5 mg/0.5 ml pens with an ultimate completion date of September 8, 2025. The order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Trulicity is a widely-used injectable diabetes medication, reflecting the company's role as a...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $7,291.68 to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 mL pens on August 25, 2025, with completion anticipated by August 26, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Trulicity is a branded diabetes medication commonly used in military...
- The Defense Logistics Agency awarded a delivery order valued at $1,644.14 to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 mL pens on July 17, 2025. This competitively awarded, firm fixed-price delivery order is set to be completed by July 18, 2025, with the product to be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $7,755.09 to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 ml pens on August 21, 2025, with completion expected by August 22, 2025. This non-competitive, firm fixed-price delivery order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB25FKUBVDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,458.30 to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 mL pens on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price delivery order represents a non-competitive award issued under a larger contract vehicle and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. Trulicity is a prescription diabetes medication commonly used within military healthcare systems and Department of Defense medical supply chains. This delivery order is issued under AmerisourceBergen's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains to military healthcare programs worldwide. The company's competitively awarded contract portfolio with DLA demonstrates its established capability to meet federal pharmaceutical supply requirements efficiently and reliably.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 7/24/25 |